Alembic Pharmaceuticals Limited has informed the Exchange that Board of Directors at its meeting held on May 15, 2026, recommended Final Dividend of Rs. 12 per equity share.
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Alembic Pharmaceuticals reported FY2026 standalone revenue of Rs. 6,651 crore, up 10.3% YoY from Rs. 6,033 crore. Consolidated revenue was Rs. 7,345 crore (up 10.1% YoY). Standalone PAT grew 27.3% to Rs. 640 crore versus Rs. 503 crore last year. EBITDA margin expanded from 15.74% to 16.82% while net profit margin improved from 8.34% to 9.63%. The Board recommended a final dividend of Rs. 12 per share (600%), up from Rs. 11 (550%) last year. Exceptional items included Rs. 48.64 crore for new Labour Code provisions and Rs. 18.35 crore write-down on Sikkim facility assets held for sale, partially offset by Rs. 100.27 crore deferred tax asset recognition. Auditors issued an unmodified opinion.
Strong earnings with PAT growth exceeding 25% and margin expansion signals operational efficiency. Dividend increase reflects healthy cash generation. The Sikkim facility write-down is non-recurring.